About vétoquinol sa - VETOF
Vétoquinol SA operates as a global animal health company. It supplies drugs and nonmedicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets. The firm designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region. It also manufactures antibiotic, anti-inflammatory, cardiology, and nephrology drugs. The company was founded by Joseph Frechin in 1933 and is headquartered in Lure, France.
VETOF At a Glance
Vétoquinol SA
34, rue du Chêne Sainte-Anne
Lure, Bourgogne-Franche-Comte 70200
| Phone | 33-3-84-62-55-55 | Revenue | 593.28M | |
| Industry | Pharmaceuticals: Major | Net Income | 64.74M | |
| Sector | Health Technology | 2025 Sales Growth | 1.72% | |
| Fiscal Year-end | 12 / 2026 | Employees | 2,501 | |
| View SEC Filings |
VETOF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
VETOF Efficiency
| Revenue/Employee | 237,216.165 |
| Income Per Employee | 25,883.739 |
| Receivables Turnover | 4.689 |
| Total Asset Turnover | 0.712 |
VETOF Liquidity
| Current Ratio | 3.08 |
| Quick Ratio | 2.26 |
| Cash Ratio | 1.487 |
VETOF Profitability
| Gross Margin | 30.505 |
| Operating Margin | 13.932 |
| Pretax Margin | 14.343 |
| Net Margin | 10.911 |
| Return on Assets | 7.765 |
| Return on Equity | 10.03 |
| Return on Total Capital | 9.086 |
| Return on Invested Capital | 9.866 |
VETOF Capital Structure
| Total Debt to Total Equity | 2.586 |
| Total Debt to Total Capital | 2.521 |
| Total Debt to Total Assets | 2.003 |
| Long-Term Debt to Equity | 1.413 |
| Long-Term Debt to Total Capital | 1.378 |